|
NEXMED FILES NDA
FOR PROPRIETARY ERECTILE DYSFUNCTION
TREATMENT
|
|
East Windsor,
NJ, September 24, 2007 --
NexMed, Inc. (Nasdaq: NEXM),
a developer of innovative transdermal
products based on its proprietary
NexACT drug delivery technology,
today announced that it filed
the New Drug Application (NDA)
for its topically applied alprostadil
cream for the treatment of erectile
dysfunction with the U.S. Food
and Drug Administration (FDA)
on September 21, 2007. The FDA
customarily accepts or refuses
an NDA and designates review
status within sixty (60) days
of filing. Once accepted, the
standard review time by the
FDA is twelve (12) months.
|
|
|
|
| About NexMed,
Inc. |
|
| NexMed, Inc. is an emerging
drug developer that is leveraging
its proprietary drug technology
to develop a significant pipeline
of innovative pharmaceutical products
to address significant unmet medical
needs. The Company is also working
with various pharmaceutical companies
to explore the incorporation of
NexACT into their existing drugs
as a means of developing new patient-friendly
transdermal products and extending
patent lifespans and brand equity. |
|
|
|
|
